We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 52.00 | 0.48% | 10,914.00 | 10,918.00 | 10,922.00 | 11,018.00 | 10,858.00 | 10,946.00 | 2,417,068 | 16:35:15 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 28.43 | 169.28B |
From Apr 2022 to Apr 2024
By Kyle Morris
AstraZeneca PLC said Monday that a Lynparza combination has been recommended for marketing authorization in the European Union for the treatment of metastatic castration-resistant prostate cancer.
The Anglo-Swedish pharma major said Lynparza in combination with abiraterone and prednisone or prednisolone has been recommended by the Committee for Medicinal Products for Human Use of the European Medicines Agency for the treatment of adult patients for whom chemotherapy isn't clinically indicated.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
November 14, 2022 02:29 ET (07:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
